Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1/ CTLA-4 Bi-specific Antibody) Combined With Chemoradiotherapy Versus Chemoradiotherapy Alone in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma：A Randomized, Controlled, Multicenter Phase III Clinical Study.

NCT06749899 is registered in ClinicalTrials.gov with Sun Yat-Sen University Cancer Center as lead sponsor.

NCT NCT06749899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06749899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1/ CTLA-4 Bi-specific Antibody) Combined With Chemoradiotherapy Versus Chemoradiotherapy Alone in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma：A Randomized, Controlled, Multicenter Phase III Clinical Study.
Lead sponsor
Sun Yat-Sen University Cancer Center
Phase
Phase 3
Overall status
Recruiting
Start date
May 4, 2025
Completion date
December 1, 2030
Enrollment
580 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancer, nasopharyngeal cancinoma (npc)